Welcome to our dedicated page for Tvardi Therapeutics news (Ticker: TVRD), a resource for investors and traders seeking the latest updates and insights on Tvardi Therapeutics stock.
Tvardi Therapeutics, Inc. (NASDAQ: TVRD) is a clinical-stage biopharmaceutical company whose news flow centers on the development of oral small molecule therapies targeting STAT3 for fibrosis-driven diseases and oncology indications. Company press releases consistently describe Tvardi as focused on STAT3, a transcription factor it identifies as a central mediator of fibrotic signaling pathways and as involved in cancer cell survival and immune evasion.
News updates for TVRD commonly cover progress in clinical trials of its lead STAT3 inhibitor TTI-101 and its next-generation STAT3 inhibitor TTI-109. Tvardi has issued detailed announcements on the REVERT IPF Phase 2 clinical trial of TTI-101 in idiopathic pulmonary fibrosis, including completion of enrollment, preliminary data indicating that the study did not meet its goals, and subsequent analyses examining fibrosis scores, inflammatory markers such as IL-6, and pulmonary function measures like Forced Vital Capacity. Additional news highlights the REVERT Liver Cancer Phase 1b/2 trial of TTI-101 in hepatocellular carcinoma and the initiation and progress of a healthy volunteer study of TTI-109.
Investors and followers of TVRD news can also expect regular financial and business updates, including quarterly results, cash runway disclosures, and commentary on upcoming clinical milestones. Tvardi frequently announces participation in healthcare and biotechnology investor conferences, such as events hosted by J.P. Morgan, Piper Sandler, Jefferies, Cantor and BTIG, where management provides corporate presentations and engages with investors.
This news page aggregates Tvardi’s press releases and related coverage so readers can track clinical trial developments, data readouts, regulatory milestones, and corporate communications related to its STAT3-targeted programs. For those monitoring TVRD stock, the news stream offers insight into how Tvardi’s clinical and corporate activities evolve over time.
Tvardi Therapeutics (NASDAQ: TVRD) announced that management will participate in three upcoming investor conferences in September 2026. The company will attend the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9 for 1-on-1 meetings, the Cantor Global Healthcare Conference in New York on September 10 for a fireside chat and 1-on-1 meetings at 10:55 AM ET, and the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14 for a company presentation and 1-on-1 meetings at 4:30 PM ET.
The corporate presentation and the H.C. Wainwright webcast will be available on Tvardi's investor website, with a replay accessible for about 90 days.
Tvardi Therapeutics (NASDAQ: TVRD) reported second quarter 2026 results and clinical progress for its STAT3 inhibitor programs. Topline healthy volunteer data for next-generation STAT3 inhibitor TTI-109 confirmed its prodrug design, improved tolerability versus TTI-101-equivalent exposure, and pharmacodynamic evidence of STAT3 target engagement, including reductions in immune cell populations associated with ulcerative colitis (UC) severity. Tvardi designated UC as the initial indication for TTI-109, citing STAT3’s role as a convergent disease node in UC, and plans a TTI-109 UC trial in 2027, subject to IND clearance and additional funding. Q2 2026 research and development expenses declined to $4.0 million and general and administrative expenses to $2.6 million, with a net loss of $6.5 million. Cash, cash equivalents and short-term investments were $15.8 million, which the company expects to fund operations, as currently planned, through the TTI-101 hepatocellular carcinoma Phase 1b/2 topline readout into the third quarter of 2027.
Tvardi Therapeutics (NASDAQ: TVRD) will host a KOL webinar on August 19, 2026 at 11:00 AM ET to discuss the evolving treatment landscape in ulcerative colitis (UC) and the clinical potential of its oral STAT3 inhibitor TTI-109. The event will feature gastroenterologist and mucosal immunologist Randy Longman, MD, PhD of Weill Cornell Medicine, who will review unmet needs in UC and how STAT3 inhibition may fit into future treatment paradigms.
The webinar will include new Tvardi data, a review of Phase 1 healthy volunteer results for TTI-109, and an outline of the planned clinical development strategy. According to Tvardi, a UC study of TTI-109 in moderate-to-severe patients is planned for 2027, pending IND clearance and additional funding, with safety as the primary endpoint and clinical remission at 12 weeks as a secondary endpoint.
Tvardi Therapeutics (NASDAQ: TVRD) has selected ulcerative colitis (UC) as the initial indication for its next-generation oral STAT3 inhibitor TTI-109, following completion of a Phase 1 healthy volunteer study. TTI-109 modulated multiple STAT3-driven immune cell populations, including Th17, T follicular helper (Tfh) and B cells, which are implicated in UC pathology.
Across the active dose range, Tvardi observed up to 76% reduction in pathogenic Th17 subsets, up to 43% reduction in disease-associated Tfh subsets, and up to 71% decline in B-cell subsets linked to colonic inflammation. Tvardi plans to start a trial of TTI-109 in moderate-to-severe UC in 2027, subject to IND clearance and additional funding, with safety as the primary endpoint and 12-week clinical remission as a secondary endpoint. The company highlights UC’s estimated $3 billion U.S. and $9 billion global market and notes differentiated safety across more than 400 subjects treated with its STAT3 inhibitors to date. Tvardi will also host a KOL webinar on Wednesday, August 19, at 11:00 a.m. ET to review new TTI-109 data and the UC treatment landscape.
Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 data for TTI-109, a phosphate prodrug of STAT3 inhibitor TTI-101. TTI-109 showed rapid conversion to TTI-101, near-identical exposure at molar-equivalent doses, stable 21-day pharmacokinetics and up to 60% reductions in STAT3-driven Th17, Tfh and B cell populations.
Diarrhea duration was shorter with TTI-109 than TTI-101 (0.46 vs. 3.35 days). Tvardi plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases, subject to additional funding and IND clearance.
Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharma company targeting STAT3 for inflammatory and proliferative diseases, will take part in two June 2026 investor events.
Management will join fireside chats at the Jefferies Global Healthcare Conference and the Raymond James BioPharma CEO Strategy Series, with live webcasts and 90-day replays.
Tvardi Therapeutics (NASDAQ: TVRD) reported Q1 2026 results and a business update. Key near-term catalysts include TTI-109 healthy volunteer topline data expected in June 2026 and a planned clinical development strategy, and TTI-101 Phase 1b/2 HCC topline results expected in 2H 2026.
Q1 figures: R&D $4.9M, G&A $2.1M, net loss $6.8M (loss per share $(0.73)), and cash/short-term investments $25.0M, with management stating runway into Q4 2026.
Tvardi Therapeutics (NASDAQ: TVRD) will participate in one-on-one investor meetings at the Raymond James Biotech Innovation Symposium in New York City on April 14, 2026. Tvardi is a clinical-stage biopharmaceutical focused on oral small-molecule therapies targeting STAT3 for inflammatory and proliferative diseases.
Tvardi Therapeutics (NASDAQ: TVRD) reported fourth-quarter and full-year 2025 results and provided a clinical update. Cash, cash equivalents and short-term investments were $30.8M as of Dec 31, 2025, with a runway expected into Q4 2026. Net loss for 2025 was $18.2M versus $29.4M in 2024.
Clinical milestones: topline healthy volunteer data for next-generation STAT3 inhibitor TTI-109 expected in Q2 2026; topline Phase 1b/2 REVERT LIVER CANCER results for TTI-101 anticipated in H2 2026. REVERT IPF analysis showed a 9.4% fibrosis reduction vs 2.4% for placebo.
Tvardi Therapeutics (NASDAQ: TVRD) announced management will participate in four investor events in February–March 2026: JonesTrading C-Suite (Feb 19), Oppenheimer Healthcare Life Sciences (Feb 25), TD Cowen Health Care (Mar 3) and Barclays Global Healthcare (Mar 10).
Webcasts for JonesTrading and Oppenheimer will stream on the Tvardi investors website, with replays available for about 90 days.